Isocitrate dehydrogenase inhibitors in acute myeloid leukemia

IDH inhibitors have shown good clinical response in AML patients. Based on phase 1/2 clinical trials, enasidenib and ivosidenib have been approved by the Food ...

Management of isocitrate dehydrogenase 1/2 mutated acute ...

Acute myeloid leukemia (AML) is a hematologic malignancy originating at the level of the hematopoietic stem cell (HSC) with an overall incidence ...

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia - PMC

IDH inhibitors have shown good clinical response in AML patients. Hence, enasidenib and ivosidenib, the IDH2 and IDH1 inhibitors developed by Agios ...

Acute myeloid leukemia with IDH1 and IDH2 mutations - Nature

Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate ...

Efficacy and safety of FDA-approved IDH inhibitors in the treatment ...

... isocitrate dehydrogenase (IDH) inhibitors in the treatment of IDH-mutated acute myeloid leukemia (AML). We used R software to conduct a meta ...

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia

AML = acute myeloid leukemia; IDH = isocitrate dehydrogenase. IDH inhibitors as monotherapy. The IDH1 inhibitor ivosidenib and the IDH2 inhibitor enasidenib ...

Efficacy and Safety of IDH Inhibitors in AML: A Systematic Review of ...

Isocitrate dehydrogenase (IDH) gene mutation leads to the accumulation of oncometabolite. IDH 1 and 2 gene mutations are associated with ...

Efficacy and tolerability of isocitrate dehydrogenase inhibitors in ...

Younger patients with de novo AML, have an overall survival rate of 40–50 % at 5 years [2], [3], [4]. Despite many cases that respond to induction chemotherapy, ...

Clinical Implications of Isocitrate Dehydrogenase Mutations ... - MDPI

Recently, the Food and Drug Administration approved three mutant IDH (mIDH) inhibitors for the treatment of AML. However, the use of mIDH inhibitors in ...

Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in ...

Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1) enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia ( ...

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer ...

Driver mutations in IDH1 and IDH2 have been likewise identified in acute myeloid leukemia (AML), chondrosarcoma, myelodysplastic syndromes, and ...

Response Prediction to Isocitrate Dehydrogenase (IDH) Inhibitors in ...

Response prediction to isocitrate dehydrogenase (IDH) inhibitors in patients with IDH1- or IDH2-mutated acute myeloid leukemia using clinical and genomic data.

Isocitrate Dehydrogenase Inhibitor - an overview - ScienceDirect.com

5.1 Question: what is the role of IDH inhibitors in AML? ... Isocitrate dehydrogenase (IDH) catalyzes the conversion of isocitrate to alpha ketoglutarate. IDH ...

Isocitrate dehydrogenase-1 (IDH1) inhibitors | DrugBank Online

An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation. Olutasidenib ...

Discovery and Optimization of Allosteric Inhibitors of Mutant ...

Discovery and Optimization of Allosteric Inhibitors of Mutant Isocitrate Dehydrogenase 1 (R132H IDH1) Displaying Activity in Human Acute Myeloid ...

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia - Frontiers

Recently, the discovery of biological and clinical properties of mutated isoforms 1 and 2 mutations of isocitrate dehydrogenases (IDH) 1 and 2, ...

Efficacy and Tolerability of Isocitrate Dehydrogenase Inhibitors in ...

Efficacy and Tolerability of Isocitrate Dehydrogenase Inhibitors in Patients With Acute Myeloid Leukemia: A Systematic Review of Clinical Trials ...

IDH Inhibitors in AML - Clinical Lymphoma, Myeloma and Leukemia

1 Isocitrate dehydrogenase (IDH) 1 and 2 mutations are found in 20% of AML patients, and occur more frequently in older in- dividuals.2 They are most commonly ...

"Preclinical Studies Of A Novel Idh1 Inhibitor In Acute Myeloid ...

LY3410738, a novel covalent Isocitrate Dehydrogenase 1 (IDH1) inhibitor in Acute Myeloid Leukemia, it is more effective than Ivosidenib (AG120) and has a ...

Isocitrate Dehydrogenase-1 Inhibitors | DrugBank Online

An isocitrate dehydrogenase-1 inhibitor used to treat acute myeloid leukemia and cholangiocarcinoma in adults with a susceptible IDH1 mutation. Olutasidenib ...